Genvoya — Total revenues
Gilead Sciences Genvoya — Total revenues decreased by 30.5% to $264.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.5%, from $364.00M to $264.00M. Over 3 years (FY 2022 to FY 2025), Genvoya — Total revenues shows a downward trend with a -14.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in revenue signals strong market adoption, effective competitive positioning, or successful lifecycle management, while a decrease may indicate patent expiration, increased competition from generic or newer therapies, or shifting clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated by a specific pharmaceutical product line within the company's HI...
Peer comparison
Comparable to product-specific revenue reporting in other major biopharmaceutical firms, often benchmarked against the revenue trajectories of competing branded therapies in the same therapeutic class.
gild_segment_genvoya_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $601.00M | $601.00M | $601.00M | $601.00M | $515.00M | $515.00M | $515.00M | $515.00M | $403.00M | $440.00M | $449.00M | $470.00M | $364.00M | $377.00M | $377.00M | $380.00M | $264.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -14.3% | +0.0% | +0.0% | +0.0% | -21.7% | +9.2% | +2.0% | +4.7% | -22.6% | +3.6% | +0.0% | +0.8% | -30.5% |
| YoY Change | — | — | — | — | -14.3% | -14.3% | -14.3% | -14.3% | -21.7% | -14.6% | -12.8% | -8.7% | -9.7% | -14.3% | -16.0% | -19.1% | -27.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's genvoya — total revenues?
- Gilead Sciences (GILD) reported genvoya — total revenues of $264.00M in Q1 2026.
- How has Gilead Sciences's genvoya — total revenues changed year-over-year?
- Gilead Sciences's genvoya — total revenues decreased by 27.5% year-over-year, from $364.00M to $264.00M.
- What is the long-term trend for Gilead Sciences's genvoya — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's genvoya — total revenues has grown at a -14.6% compound annual growth rate (CAGR), from $2.40B to $1.50B.
- What does genvoya — total revenues mean?
- The total revenue generated from sales of a specific HIV medication product.